Moody Aldrich Partners’s Kite Pharma, Inc. KITE Stock Holding History

Moody Aldrich Partners’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,720	Closed	-$593K	–	106
2017 Q2	$593K	Sell	5,720 -2,760	-33%	-$225K	0.74%	66
2017 Q1	$666K	Sell	8,480 -6,580	-44%	-$407K	1.14%	37
2016 Q4	$675K	Sell	15,060 -365	-2%	-$17.9K	0.44%	83
2016 Q3	$862K	Buy	15,425 +1,550	+11%	+$86.4K	0.6%	74
2016 Q2	$694K	Buy	+13,875	New	+$682K	0.57%	77

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Moody Aldrich Partners's KITE Position: Q3 2017 in Review

Moody Aldrich Partners sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 5,720 shares — an estimated $593K sold.

Moody Aldrich Partners first reported a position in KITE in Q2 2016 and held it in 5 quarters. The position peaked at $862K in Q3 2016. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Moody Aldrich Partners reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Moody Aldrich Partners sold 5,720 Kite Pharma, Inc. shares in Q3 2017, an estimated $593K.
Moody Aldrich Partners first reported a position in Kite Pharma, Inc. in Q2 2016 and held it in 5 quarters.
Moody Aldrich Partners's Kite Pharma, Inc. position peaked at $862K in Q3 2016.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Moody Aldrich Partners's 13F filing for Q3 2017, filed 13 Nov 2017.